Send to

Choose Destination
Eur J Endocrinol. 2016 Feb;174(2):P1-9. doi: 10.1530/EJE-15-0873. Epub 2015 Nov 12.

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.

Author information

University of Wisconsin School of Medicine and Public HealthMadison, Wisconsin, USACincinnati Children's Hospital Medical CenterCincinnati, Ohio, USAMedizinische Klinik und Poliklinik IVKlinikum der Universität München, Munich, GermanyMassachusetts General HospitalBoston, Massachusetts, UKFederal University of ParanaCuritiba, BrazilDepartment of EndocrinologySkane University Hospital, Malmö, SwedenUniversity College London Hospitaland UCL Institute of Child Health, London, UKHyogo Prefectural Kakogawa Medical CenterHyogo, JapanAarhus University HospitalAarhus, DenmarkMolecular Endocrinology Unit'Bambino Gesù' Children's Hospital, Tor Vergata University, Rome, ItalyUniversity of Manchester and Manchester Academic Health Science CentreManchester, UKUNC School of MedicineChapel Hill, North Carolina, USAUSC Leonard Davis School of GerontologyUniversity of Southern California, Los Angeles, California, USAIstanbul Faculty of MedicineIstanbul, TurkeyCentre Hospitalier Universitaire-Ste-JustineMontreal, Quebec, CanadaUniversity of CambridgeCambridge, UKIndiana University School of MedicineIndianapolis, Indiana, USAPerelman School of MedicineChildren's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USABaylor College of MedicineHouston, Texas, USAChristie Hospital NHS Foundation TrustManchester, UKPrincess Alexandra HospitalBrisbane, Queensland, AustraliaStanford University School of MedicineStanford, California, AustraliaErasmus University Medical CenterRotterdam, The NetherlandsDepartment of EndocrinologySahlgrenska Academy, Sahlgrenska University Hospital and Institute of Medicine, University of Gothenburg, Gothenburg, SwedenDepartment of Growth and Reproduction and EDMaRCRigshospitalet, København, DenmarkEdison Biotechnology InstituteOhio University, Athens, Ohio, USAPenn State College of MedicineHershey Medical Center, Hershey, Pennsylvania, USAMcGill UniversityLondon, UKJohns Hopkins University School of MedicineBaltimore, Marylan


Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Sheridan PubFactory Icon for PubMed Central
Loading ...
Support Center